Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2356036 | 0.85 | ABL1 (0.42) | RAB9ASMN1; SMN2ALDH1A1KDM4EGABRA1 | |
| SCHEMBL1320678 | 0.84 | KMT2A (0.47) | NPC1RAB9ASMN1; SMN2GAAKMT2A | |
| SCHEMBL1320622 | 0.84 | GAA (0.47) | NPC1RAB9ASMN1; SMN2GAAKMT2A | |
| SCHEMBL1319548 | 0.84 | SMN1; SMN2 (0.52) | NPC1RAB9ASMN1; SMN2GAAKMT2A | |
| SCHEMBL9893201 | 0.83 | ABL1 (0.46) | RAB9ASMN1; SMN2ALDH1A1KDM4EGABRA1 | |
| SCHEMBL1321828 | 0.82 | KCNQ2 (0.43) | KMT2AMEN1HPGDGABRA1GABRB2 | |
| SCHEMBL1319379 | 0.82 | CSNK1D (0.42) | ALDH1A1GABRA1GABRB2RXFP1 | |
| SCHEMBL1321097 | 0.82 | NPC1 (0.45) | NPC1RAB9ASMN1; SMN2GAAKMT2A | |
| SCHEMBL1319731 | 0.82 | GAA (0.45) | NPC1RAB9ASMN1; SMN2GAAKMT2A | |
| SCHEMBL1322691 | 0.81 | ALDH1A1 (0.45) | NPC1RAB9ASMN1; SMN2GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9018208-B2 | Heterocycles as potassium channel modulators | ICAGEN INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-20130143889-A1 | Heterocycles As Potassium Channel Modulators | ICAGEN INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-8431608-B2 | Heterocycles as potassium channel modulators | ICAGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| EP-2178373-B1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN INC (US) | 2013-01-23 | — | — | EP | disclosed |
| EP-2536718-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | Icagen, Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| US-8058274-B2 | Heterocycles as potassium channel modulators | ICAGEN, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| WO-2011102964-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| US-20100240663-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| EP-2178373-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | Icagen, Inc. (US) | 2010-04-28 | — | — | EP | disclosed |
| US-20090062290-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| WO-2009026254-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143889-A1 | Heterocycles As Potassium Channel Modulators | KCNK10, KCNK9, KCNJ2 | NPC1 1912/4885RAB9A 664/4885SMN1; SMN2 187/4885 |
| US-20090062290-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNK2, KCNK17 | NPC1 1731/4885RAB9A 996/4885SMN1; SMN2 135/4885 |
| US-20100240663-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNK2, KCNK17 | NPC1 1731/4885RAB9A 996/4885SMN1; SMN2 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.